MET and non-small cell lung carcinoma: Similarly, the NMPA has authorized savolitinib,324 gumarontinib325 and vebreltinib326 for treating metastatic NSCLC with MET exon 14 skipping, based on the promising improvements in ORR and PFS, albeit with enrollment numbers being less than 90 for each study.